{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:21:34Z","timestamp":1787937694842,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-05167-2","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:40:05Z","timestamp":1787892005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Behavior change support in the new era of obesity care"],"prefix":"10.1186","volume":"24","author":[{"given":"Brunna","family":"Boaventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart W","family":"Flint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"5167_CR1","volume-title":"WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. Geneva: World Health Organization; 2025. https:\/\/app.magicapp.org\/#\/guideline\/LrRxrL. Accessed 11 Dec 2025."},{"key":"5167_CR2","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000001221","volume":"150","author":"D Laddu","year":"2024","unstructured":"Laddu D, Neeland IJ, Carnethon M, Stanford FC, Mongraw-Chaffin M, Barone Gibbs B, et al. Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association. Circulation. 2024;150:e7\u201319. https:\/\/doi.org\/10.1161\/CIR.0000000000001221.","journal-title":"Circulation"},{"key":"5167_CR3","doi-asserted-by":"publisher","unstructured":"Cousins S. The boom in counterfeit obesity drugs. Lancet. 2026 5:S0140-6736(26)00461-7. https:\/\/doi.org\/10.1016\/S0140-6736(26)00461-7","DOI":"10.1016\/S0140-6736(26)00461-7"},{"key":"5167_CR4","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304.","journal-title":"BMJ"},{"key":"5167_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev-psych-020124-114222","volume":"76","author":"MS Hagger","year":"2025","unstructured":"Hagger MS. Psychological Determinants of Health Behavior. Annu Rev Psychol. 2025;76:821\u201350. https:\/\/doi.org\/10.1146\/annurev-psych-020124-114222.","journal-title":"Annu Rev Psychol"},{"key":"5167_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1037\/ccp0000819","volume":"91","author":"RL Pearl","year":"2023","unstructured":"Pearl RL, Wadden TA, Bach C, LaFata EM, Gautam S, Leonard S, et al. Long-term effects of an internalized weight stigma intervention: A randomized controlled trial. J Consult Clin Psychol. 2023;91:398\u2013410. https:\/\/doi.org\/10.1037\/ccp0000819.","journal-title":"J Consult Clin Psychol"},{"key":"5167_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40200-025-01770-x","volume":"24","author":"F Ameer","year":"2025","unstructured":"Ameer F, Villacres NY, Bustos D, Shah PC, Appah N, Luzaya GN, et al. Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review. J Diabetes Metab Disord. 2025;24:253. https:\/\/doi.org\/10.1007\/s40200-025-01770-x.","journal-title":"J Diabetes Metab Disord"},{"key":"5167_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41366-024-01516-4","volume":"48","author":"SM Post","year":"2024","unstructured":"Post SM, Persky S. The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. Int J Obes. 2024;48:1019\u201326. https:\/\/doi.org\/10.1038\/s41366-024-01516-4.","journal-title":"Int J Obes"},{"key":"5167_CR9","volume-title":"National Coverage Determination (NCD) for Intensive Behavioral Therapy for Obesity","author":"Centers for Medicare & Medicaid Services","year":"2011","unstructured":"Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Intensive Behavioral Therapy for Obesity. Baltimore: Centers for Medicare & Medicaid Services; 2011. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncd.aspx?NCDId=353. Accessed 08 March 2026."},{"key":"5167_CR10","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.bodyim.2025.101890","volume":"53","author":"CH Markey","year":"2025","unstructured":"Markey CH, August KJ, Malik D, Richeson A. Body image and interest in GLP-1 weight loss medications. Body Image. 2025;53:101890. https:\/\/doi.org\/10.1016\/j.bodyim.2025.101890.","journal-title":"Body Image"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-05167-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-05167-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:03:13Z","timestamp":1787936593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-05167-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5167"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-05167-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BB declares no competing interests. SWF declares no competing interests related to this article. Unrelated to this work, SWF reports researcher-led grants from the National Institute for Health Research and Novo Nordisk, and support for attending academic conferences and events from Novo Nordisk, Eli Lilly, the UK Parliament, and Welsh Parliament.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"465"}}